Loading
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$56.93
+$0.72 · +1.28%
Previous close
$56.93
+$0.72 · +1.28%
After-hours
$56.93
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
59
Fair Value
Sentiment
63
Bullish
Risk
18
Low Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Day range
Current $56.93
52-week range
Current $56.93
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.38B USD | 2.26B USD | 2.35B USD | 2.24B USD | 2.29B USD |
| Gross profit | 2.38B USD | 2.26B USD | 2.35B USD | 2.24B USD | 2.29B USD |
| Research and development | 452M USD | 2M USD | 52M USD | 177.11M USD | 200.08M USD |
| Selling, general, and administrative | 573.48M USD | 236.67M USD | 249.75M USD | 227.3M USD | 182.83M USD |
| Operating expenses | 818.68M USD | 971.13M USD | 862.4M USD | 1.93B USD | 858.75M USD |
| Interest income | 33.59M USD | 47.34M USD | 72.29M USD | 78.34M USD | 53.54M USD |
| Interest expense | 307.66M USD | 225.51M USD | 187.19M USD | 187.96M USD | 166.14M USD |
| Depreciation and amortization | 3.85M USD | — | — | 5.67M USD | 23M USD |
| Operating income | 1.56B USD | 1.29B USD | 1.49B USD | 307.07M USD | 1.43B USD |
| Net income | 770.95M USD | 858.98M USD | 1.13B USD | 42.83M USD | 619.73M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$63.33
11.24% upsideCash distributions grouped by calendar year; partial years are marked.
$0.88
2025 complete year+29.4% since 2021
2026 partial: $0.705
$0.68
2,021
$0.76
2,022
$0.80
2,023
$0.84
2,024
$0.88
2,025
$0.705
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 14, 2026 | $0.235Quarterly | Aug 14, 2026 | Sep 10, 2026 |
Dividend | May 15, 2026 | $0.235Quarterly | May 15, 2026 | Jun 10, 2026 |
Dividend | Feb 20, 2026 | $0.235Quarterly | Feb 20, 2026 | Mar 10, 2026 |
Dividend | Nov 14, 2025 | $0.22Quarterly | Nov 14, 2025 | Dec 10, 2025 |
Dividend | Aug 15, 2025 | $0.22Quarterly | Aug 15, 2025 | Sep 10, 2025 |
Dividend | May 16, 2025 | $0.22Quarterly | May 16, 2025 | Jun 10, 2025 |
Ex-dividend Aug 14, 2026
$0.235
Quarterly
Record Aug 14, 2026 · Payment Sep 10, 2026
Ex-dividend May 15, 2026
$0.235
Quarterly
Record May 15, 2026 · Payment Jun 10, 2026
Ex-dividend Feb 20, 2026
$0.235
Quarterly
Record Feb 20, 2026 · Payment Mar 10, 2026
Ex-dividend Nov 14, 2025
$0.22
Quarterly
Record Nov 14, 2025 · Payment Dec 10, 2025
Ex-dividend Aug 15, 2025
$0.22
Quarterly
Record Aug 15, 2025 · Payment Sep 10, 2025
Ex-dividend May 16, 2025
$0.22
Quarterly
Record May 16, 2025 · Payment Jun 10, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF278.19M0.29%95.4B USD0.05%$235+0.80%
VictoryShares Free Cash Flow ETFVFLO183.38M1.60%11.42B USD0.44%$52.84-0.11%
Vanguard High Dividend Yield ETFVYM103.04M0.10%100.8B USD0.04%$158.75+0.32%
iShares Russell Mid-Cap ETFIWR96.84M0.17%56.32B USD0.18%$109.82+0.87%
iShares U.S. Pharmaceuticals ETFIHE65.94M4.30%1.52B USD0.37%$100.09+1.24%
Capital Group Dividend Growers ETFCGDG65.83M1.16%5.67B USD0.47%$37.36+0.30%
iShares Russell 1000 Value ETFIWD52.03M0.06%82.44B USD0.18%$253.54+0.61%
iShares MSCI USA Momentum Factor ETFMTUM36.78M0.18%20.1B USD0.15%$320+0.84%Vanguard Extended Market ETFVXFVictoryShares Free Cash Flow ETFVFLOVanguard High Dividend Yield ETFVYMiShares Russell Mid-Cap ETFIWRiShares U.S. Pharmaceuticals ETFIHECapital Group Dividend Growers ETFCGDGiShares Russell 1000 Value ETFIWDiShares MSCI USA Momentum Factor ETFMTUMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
